Cart  |  Log In

Applications | Features | Rewards | LabFacts | FAQs | Cartoons | Subscribe | Site Help | RSS

 

Busy?
Don't miss an article!
Get eNotes updates.

 

Focus: Automated Cell-Based Assays

Automating Cell-Based Assays in Multiwell Format

We demonstrate the use of liquid handling workstations for performing cell-based assays. The feasibility of scale-up and minimal manipulation required to perform these assays makes them candidates for implementation on a variety of automated workstations. This article specifically describes the adaptation of Promega cell-based assays to the Beckman Coulter Biomek® 2000 and FX workstations in both 96- and 384-well formats.

By Tracy Worzella, B.S. and Brad Larson, B.A., Promega Corporation


Introduction

Cell-based assays have become a quick, lower-cost means to test hit or lead compounds for toxic effects before proceeding with drug development. The term “cell-based assay” describes any procedure that uses 
live cells for the evaluation of effects on toxicity, viability, proliferation or other specific cellular processes following the addition of a test compound. Of particular interest in drug discovery is the ability to analyze ADME/Tox (Absorption, Distribution, Metabolism, Elimination/Toxicity) properties for compounds of interest. Cell-based assays provide a platform in which these properties and processes can be tested.

The process of performing a cell-based assay generally includes plating cells, equilibrating to culture conditions, adding a test compound, and measuring output from treatment. These assays can be made easier by automating the process. Depending on the needs and financial resources of the user, a single step or multiple steps of the assay process can be adapted to an automated workstation. These workstations, whether they are liquid handlers or fully-integrated systems with incubators, shakers and plate readers, allow increased throughput for sample processing. Automation also removes the requirement for hands-on assay performance, resulting in less error and higher reproducibility.

We have incorporated and validated several Promega cell-based assays on the Beckman Coulter Biomek® 2000 and FX automated workstations in both 96- and 384-well formats to meet the varying needs of the automation user. Table 1 highlights the assays that we have automated and validated on the Biomek® platforms. Using these cell-based assay reagents, we have automated the final step 
in the assay process, allowing the measurement of output following treatment. The simple and scalable “add-mix-measure” cell viability and apoptosis assay formats make these assays ideal for multiwell plates and high-throughput screening on any workstation.

Table 1. Promega Automated Cell-Based Assays. The assays listed are validated on the Biomek® 2000 and FX platforms in both 96- and 384-well formats.

Assay

Type

Assay
Measurement

Output

Caspase-Glo™ 3/7 Assay

Apoptosis

Caspase-3/7
Activity

Luminescent

Apo-ONE® Homogeneous Caspase-3/7 Assay

Apoptosis

Caspase-3/7
Activity

Fluorescent

CytoTox-ONE™ Homogenous Membrane Integrity Assay

Membrane
Integrity

LDH Release

Fluorescent

CellTiter-Glo® Luminescent Cell Viability Assay

Cell Viability

ATP

Luminescent

CellTiter-Blue™ Cell Viability Assay

Cell Viability

Metabolic Capacity/
Resazurin Reduction

Fluorescent

Automated Method Development

Automated, single-plate methods were developed for five Promega cell-based assays in 96- and 384-well format on the Biomek® 2000 and FX workstations. Each method is a computer program that the robot will follow in order to perform the assay. These instructions encompass all the liquid handling steps, physical manipulations of each assay plate across the deck and operation of any devices on the deck.

To perform a cell-based assay on an automated workstation, the deck of the workstation is manually 
set up by adding labware, reagents, tip boxes and the sample plate. Once the method is started, the robot will perform all steps without the need for manual intervention. Due to the simplicity of the assays being automated, and the methods written for each assay, the number of deck positions required to perform each assay is minimal. Typically, only 3 to 4 deck positions are required for the single-plate Biomek® 2000 and FX methods (Figure 1). While this number may vary depending on the method, each automated assay will fit onto any deck layout that a robotic platform may have. This will also make it possible to create multiplate methods that are able to fit onto the original deck layout without the need for stacking capabilities.

The automated cell-based assay methods we developed perform three steps on the robotic platform (Table 2). Additional steps, including assay plate incubations and recording data from fluorescent or luminescent assays, are performed offline (separate from the robotic platform). These steps can be automated, depending on the level of automation required on the robotic platform being used. This fact, along with the methods’ simplicity, and minimal deck requirements, allows these assays to meet the needs of low-, medium-, or high-throughput research laboratories.

Validated methods to run these assays and other chemistries are available for download at www.promega.com/automethods/. In addition, the hardware, labware requirements and instructions are available as automated protocols and are available at www.promega.com/tbs/.

Table 2. General Method for Single-Plate Automated Cell-Based Assays.
  1. Transfer volume of reagent prescribed in the Automated Protocol to the assay plate containing blank, control, cell culture, or purified enzyme suspension.
  2. Transfer the assay to the orbital shaker on the robotic platform, and mix reagent and samples.
  3. Transfer the assay plate back to its original position on the deck.
The assays include an incubation period, which varies with the assay. The CytoTox-ONE™ Assay includes an optional addition of Stop Solution at the conclusion of the method.

Validation and Results 

Each single-plate method was validated according to the performance criteria for each assay. Validation of these methods provides confidence that the methods have been thoroughly tested and will provide consistent, reproducible results in any setting. Results indicate that these automated assays provide reproducible data that often equals or exceeds that achieved when performing the assays manually (data not shown). This also represents a time savings to researchers by allowing them to proceed directly to sample processing.

The criteria that we use for validation include the sensitivity of each assay, as well as linearity across a set range of cell or purified enzyme concentrations. Assay robustness and reproducibility are tested as well using Z´-factor determination (1).

The Z´-factor is a statistical value used to determine an assay’s robustness and reproducibility by comparing its dynamic range to the data variation. A Z´-factor value of 1.0 indicates a perfect assay. A Z´-factor value greater than 0.5 indicates excellent assay quality.

The Z´-factor was determined for each automated assay. Analyses were completed in 96- and 384-well formats using the Biomek® 2000 and Biomek® FX platforms. The results from each analysis are shown in Table 3. All assays and formats had a Z´-factor greater than 0.5.

Table 3. Z´-Factor for Automated Cell-Based Assays developed on the Biomek® 2000 and FX platforms.

Automated Assay

Cell-Based Paltform

Robotic Well Format

Assay Plate Z´-Factor

Caspase-Glo™ 3/7 Assay

Biomek® 2000

Biomek® FX

96
384
96
384

0.63
0.62
0.90
0.84

       

Apo-ONE® Homogeneous Caspase-3/7 Assay

Biomek® 2000

Biomek® FX

96
384
96
384

0.80
0.58
0.77
0.76

       

CytoTox-ONE™ Homogenous Membrane Integrity Assay

Biomek® 2000

Biomek® FX

96
384
96
384

0.56
0.68
0.68
0.61

       

CellTiter-Glo® Luminescent Cell Viability Assay

Biomek® 2000

Biomek® FX

96
384
96
384

0.76
0.61
0.80
0.70

       

CellTiter-Blue™ Cell Viability Assay

Biomek® 2000

Biomek® FX

96
384
96
384

0.88
0.70
0.90
0.77

Summary

We have demonstrated the ability to automate Promega’s cell-based assays in both 96- and 384-well formats. Z´-factors for each assay format were above 0.5, indicating that they were all excellent assays. 
The minimal deck requirements of the automated methods for these cell-based assays make them flexible enough to meet the needs of low-, medium- or high-throughput laboratories.

Reference

  1. Zhang, J. et al. (1999) J. Biomol. Screening 4, 67–73.
Products may be covered by pending or issued patents or may have certain limitations on use. Please visit our patent and trademark web page for more information.
Apo-ONE and CellTiter-Glo are trademarks of Promega Corporation and are registered with the U.S. Patent and Trademark Office. Caspase-Glo, CellTiter-Blue and CytoTox-ONE are trademarks of Promega Corporation.
Biomek is a registered trademark of Beckman Coulter, Inc.

 

E-mail This Page
Printable Version

 

Figure 1. General deck configurations for cell-based assays on the Beckman Coulter Biomek® 2000 and Biomek® FX.